Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer
1 clinical trials · Condition
◉ Watch Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer
| Record | Firm | Date |
|---|---|---|
| Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer (NCT06522919) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2025-01-07 |
Track Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer automatically
Every clearance here is in the API, with alerts when new ones post.